Desvenlafaxine Succinate Hydrate

琥珀酸去甲文拉法辛

Report date: 2023/12/13 13:41:04
NME

Base Information

Drug NameDesvenlafaxine Succinate Hydrate
Drug Alias Name水合琥珀酸去甲文拉法辛Desvenlafaxine Succinate琥珀酸去甲文拉法辛水合物琥珀酸地文拉法辛琥珀酸去甲基文拉法辛 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin transporter inhibitorsNorepinephrine transporter inhibitors
TargetsNorepinephrine transporterSerotonin transporter
Therapy Area/IndicationsVasomotor symptomMenopausal symptomsDepressive Disorder, Major +[10] 
Global Approved IndicationsDepressive Disorder, MajorDepressive Disorder
Approved Indications in ChinaDepressive Disorder
Original Approved Country/TerritoryUnited States
Original Approved Date2008/02/29
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesYichang Humanwell Pharmaceutical Co LtdPf Prism CvCspc Ouyi Pharmaceutical Co Ltd +[5] 
Inactive CompaniesWyeth LlcPfizer Inc
Active IndicationsDepressive Disorder, MajorDepressive DisorderDepression
Inactive IndicationsVasomotor symptomMenopausal symptomsPain +[7] 

Other Information

ATC CodeN06AX23
Related LinksWikipediaDrugBankKEGG